A clinical trial of cannabinoid-based product for prevention of SARS-CoV-2 (COVID-19)
Latest Information Update: 04 Feb 2022
At a glance
- Drugs Cannabinoid therapeutic Flora Pharma (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 04 Feb 2022 New trial record
- 02 Feb 2022 According to a Flora Growth Corp media release, the company to seek approval for cannabinoid-based product clinical trial under an EUA from INVIMA (Colombian FDA).